Shini Liu

No.106 Zhongshan Er Road, Yuexiu District
Guangzhou, 510080, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Analysis of the predictive effect of gut microbiota changes on the occurrence of chemotherapy resistance in pancreatic cancer patients based on nomogram prediction models.

Analysis of the predictive effect of gut microbiota changes on the occurrence of chemotherapy resistance in pancreatic cancer patients based on nomogram prediction models.

Journal: BMC cancer
Published: July 27, 2025

CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer.

CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 10, 2024

Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer.

Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 30, 2024

4EBP1-mediated SLC7A11 protein synthesis restrains ferroptosis triggered by MEK inhibitors in advanced ovarian cancer.

4EBP1-mediated SLC7A11 protein synthesis restrains ferroptosis triggered by MEK inhibitors in advanced ovarian cancer.

Journal: JCI insight
Published: November 27, 2023

Targeting AURKA to induce synthetic lethality in CREBBP-deficient B-cell malignancies via attenuation of MYC expression.

Targeting AURKA to induce synthetic lethality in CREBBP-deficient B-cell malignancies via attenuation of MYC expression.

Journal: Oncogene
Published: August 22, 2023

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.

Journal: Clinical epigenetics
Published: November 03, 2022

EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.

EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.

Journal: Molecular cancer
Published: November 02, 2022

RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer.

RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer.

Journal: The Journal of clinical investigation
Published: February 23, 2022

CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma.

CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma.

Journal: Cancer letters
Published: May 25, 2021

Inhibition of the PLK1-Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer.

Inhibition of the PLK1-Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: February 24, 2021

Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer.

Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer.

Journal: The Journal of clinical investigation
Published: October 12, 2020
Showing 1-11 of 11

Last Updated: 09/26/2026